Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Ruxolitinib / opzelura for treating non-segmental vitiligo in people 12 years and over

As of August 2025, MARA’s assessment finds Ruxolitinib / Opzelura’s reimbursement risk concentrated in care pathway integration, with safety and adverse effects a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs evidence quality and robustness: how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached. The strength recorded in safety and adverse effects carries weight because that domain asks what harms arrive alongside the benefit, which payers set against the gains before funding a treatment.

Dermatology

This rating sits within MARA’s Dermatology coverage, alongside 13 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Ruxolitinib cream shows comparable efficacy to existing options, specifically vehicle cream, as evidenced by the TRuE-V trials where it significantly improved repigmentation. However, the evidence for its effectiveness compared to phototherapy is uncertain due to the lack of robust comparative data, leading to a rating of B++.

Does the economic case hold at the expected price? — Cost effectiveness

The cost-effectiveness estimates for ruxolitinib cream are uncertain and exceed NICE’s acceptable thresholds. The most likely ICER is higher than what is considered acceptable for NHS resources, leading to a B++ rating due to the need for price adjustments.

Is there quality-of-life evidence payers weigh? — Quality of life

The evidence suggests potential improvements in quality of life, particularly for individuals with black and brown skin tones, but the data is highly uncertain and lacks direct measures of HRQoL. The committee noted that existing measures may not fully capture the psychosocial burden of vitiligo, resulting in a B+ rating.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Ruxolitinib cream has a good safety profile with mostly mild adverse events reported in the TRuE-V trials. Serious adverse events were noted but not directly linked to the treatment, justifying a rating of A+.

Was the drug compared against what payers expect? — Comparator Selection

The primary comparator was vehicle cream, which is appropriate, but the lack of robust evidence comparing ruxolitinib cream to phototherapy limits the strength of the evidence. This leads to a B++ rating.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trials included a representative population of individuals aged 12 and over with non-segmental vitiligo. However, concerns about the generalizability of results to specific subgroups, particularly those with varying skin tones, lead to a rating of A.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Ruxolitinib cream is positioned as a secondary-care treatment, which may require adjustments in current care pathways. The integration is feasible but not seamless, resulting in a B+ rating.

Are the wider system costs understood? — Resource Use and Cost Implications

The economic model presented significant uncertainties regarding resource use and costs, particularly in relation to phototherapy and psychological support. This uncertainty leads to a B++ rating.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

While the evidence from the TRuE-V trials is robust, concerns about the economic model and the lack of direct HRQoL measures introduce uncertainty, justifying a B+ rating.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

There are significant uncertainties regarding the cost-effectiveness and broader impacts of ruxolitinib cream, particularly concerning its effects on different demographic groups. This leads to a B+ rating.

Be alerted when this rating changes:

Sample two-page MARA Rating report for the fictional drug Samplinib: the rating with its decision record, and the ten graded payer questions with the reasoning behind each
Every MARA rating is delivered as a two-page reasoned report (sample, fictional product) — see it in full

Public record

The entries below are official decisions and assessments concerning this drug and indication, listed with their dates as a matter of record. The assessment on this page reflects the evidence available as of its date.

  • 17 March 2026 — United Kingdom (NICE), technology appraisal TA1140: recommended with conditions. official record
Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.